Orthobiologics Market Research Report, Analysis, Size, Share, Growth by Forecast to 2026
Orthobiologics Market Overview:
The global Orthobiologics
Market, valued at $5.4 billion in 2021, is expected to grow
at a rate of 7% annually through 2026. This growth is driven by factors such as
an increasing number of sports injuries and road accidents, a growing elderly
and obese population, a rising prevalence of arthritis and spine-related
disorders, patient preference for minimally invasive procedures, and
advancements in biomaterials technology.
Unlock
Insights for 2026 — Year-End Discounts on Premium Market Reports!
Orthobiologics involves using biomaterials and
cell-based therapies to accelerate the healing of musculoskeletal injuries.
These treatments are derived from naturally occurring substances in the body,
which interact with the musculoskeletal system to promote the repair of bones,
cartilage, ligaments, tendons, and menisci. These products are widely used in orthopedic
procedures to support tissue regeneration and healing.
Technological Advancements Fueling
Growth in the Orthobiologics Market
Advancements in orthobiologics have led to the
development of more effective products with enhanced healing capabilities and a
broader range of applications. These innovations provide a competitive edge for
manufacturers, prompting ongoing investment in research and the development of
new products. Key technological developments include:
- October 2022: Paragon 28 launched the V92-FC+ Cellular Bone
Matrix, a moldable allograft matrix with primitive cells, designed to
treat bone defects and remodeling in the foot and ankle.
- June 2022: Royal Biologics received FDA 510(k) clearance for
its MAXX-BMC system, a bone marrow aspirate concentration system that
enables optimal sample collection from patients during procedures.
- June 2022: Istos Biologics launched the Influx Fibrant line
of 100% cortical allografts, featuring patented technology to support
patient healing.
- March 2022: SeaSpine introduced NorthStar cervical facet
fusion and Flash navigation lumbar facet fusion systems to improve
procedural workflows and enhance fusion success rates.
- September 2020: Cerapedics’ i-FACTOR+ Matrix bone graft, approved
by Health Canada, is designed to support bone growth using a P15
osteogenic peptide for cell attraction, attachment, and activation.
Key Growth Strategies by Market
Leaders
Leading companies in the orthobiologics sector are
adopting strategic acquisitions and partnerships to expand their product
portfolios, increase market reach, and co-develop new technologies. Some
notable moves include:
- October 2022: HippoFi (formerly ORHub) entered into a strategic
agreement with Precision Spine to market biological solutions for spine
surgery through Precision’s extensive presence in the spine market.
- August 2022: Orthofix Medical partnered with CGBio, a
synthetic bone graft developer, to co-develop and commercialize bone
growth solutions for the US and Canadian markets.
- July 2021: Celularity Inc. and Arthrex, Inc. formed a
partnership to distribute placental-derived biomaterials for orthopedic
and sports medicine applications in the US.
- April 2022: Isto Biologics acquired TheraCell, Inc.,
expanding its portfolio of orthopedic grafts.
- March 2021: SeaSpine Holdings Corporation acquired 7D
Surgical, a Canadian medical device company, aiming to combine spinal
implants with orthobiologics to improve spine surgery.
North America’s Dominance and Asia
Pacific's Growth Potential
North America holds the largest share of the global
orthobiologics market, driven by widespread adoption of biologics for treating
bone disorders, favorable reimbursement policies, and a high incidence of
arthritis and sports injuries. However, the Asia Pacific region is poised to
experience the fastest growth due to an aging population, rising obesity rates,
increasing prevalence of bone diseases, greater healthcare spending, and higher
disposable incomes. Additionally, the growing presence of major market players
in the region will further accelerate growth.
Impact of COVID-19 on the
Orthobiologics Market
The COVID-19 pandemic negatively impacted the
orthobiologics market, primarily due to a reduction in patient visits and
disruptions to supply chains, leading to a decline in sales for some companies.
For example, Orthofix Medical saw an 11% decrease in revenue in 2020 compared
to 2019 but recovered in 2021 with a 14% increase in sales. Despite these
challenges, demand for orthobiologics rebounded in 2021 as patient volumes increased
and government restrictions eased.
Growth Prospects Despite Challenges
While challenges such as unfavorable reimbursement
policies and pricing pressures remain, the orthobiologics market is expected to
continue growing, particularly in the spinal fusion segment, the use of
demineralized bone putties, viscosupplements, and innovations aimed at
simplifying procedures. For example, the viscosupplements segment is projected
to grow due to advancements in hyaluronic acid-based therapies and the rising preference
for non-surgical treatments for osteoarthritis.
Additionally, conventional techniques like autografts
and allografts, though effective, are complex, painful, and often require
repeat surgeries. As a result, there is increasing demand for more straightforward,
cost-effective solutions that are easier to manage and yield better outcomes,
creating opportunities for market players.
Browse Report: https://meditechinsights.com/orthobiologics-market/
Competitive Landscape
The orthobiologics market is highly competitive, with
established players such as Medtronic Plc (Ireland), Zimmer Biomet Holdings,
Inc. (US), Arthrex, Inc. (US), Bioventus (US), DePuy Synthes (Johnson &
Johnson Services, Inc.) (US), Stryker Corporation (US), MTF Biologics (US), and
others playing significant roles in driving innovation and market expansion.
Related Report:
HPV Testing and PAP Test Market https://www.pharmiweb.com/press-release/2025-12-18/hpv-testing-and-pap-test-market-share-size-growth-forecast-till-2030
Cellular Health Screening Market https://www.pharmiweb.com/press-release/2025-12-18/cellular-health-screening-market-2030-analysis-size-share-growth-trends-and-forecast
Hematology Market https://www.pharmiweb.com/press-release/2025-12-18/hematology-market-outlook-2030-industry-trends-and-competitive-analysis
Long-Term Care Software Market https://www.pharmiweb.com/press-release/2025-12-18/long-term-care-software-market-demand-for-evidence-based-medicine-and-research-updates
About Medi-Tech Insights;
Medi-Tech Insights is a healthcare-focused business research &
insights firm. Our clients include Fortune 500 companies, blue-chip investors
& hyper-growth start-ups. We have completed 100+ projects in Digital
Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research
combined with deep-dive interviews with industry-leading CXO, VPs, and key
demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
Comments
Post a Comment